Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
10.1016/j.apsb.2022.07.020
- Author:
Chen FU
1
;
Lifeng YU
1
;
Yuxi MIAO
1
;
Xinli LIU
2
;
Zhaojin YU
1
;
Minjie WEI
1
Author Information
1. Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
2. Department of Digestive Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
- Publication Type:Review
- Keywords:
Drug;
Linker;
Peptide;
Permeability;
Stability;
Targeted therapy
- From:
Acta Pharmaceutica Sinica B
2023;13(2):498-516
- CountryChina
- Language:English
-
Abstract:
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components and functions of PDCs for therapeutic, from drug target screening and PDC design improvement strategies to clinical applications to improve the permeability, targeting, and stability of the various components of PDCs. This holds great promise for the future of PDCs, such as bicyclic peptide‒toxin coupling or supramolecular nanostructures for peptide-conjugated drugs. The mode of drug delivery is determined according to the PDC design and current clinical trials are summarised. The way is shown for future PDC development.
